Ignorance is not bliss - but this is modus vivendi [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-12-04 18:12  – Posting: # 20928
Views: 884

Hi Helmut,

» … and decide to ignore it cause nothing is (still!) given in the guidelines? OK, I know 1 (one!) company adjusting α in its studies.

This is the rhetorical question. 😺 So... Throughout the existence of the “Scientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation” I don't remember any "inhouse" guidline for bioequivalence. Just retelling EMA/FDA guidlines. From other side, officials don't like to include experts for guideline development and don't have any discussions - this does not apply to meetings of the Euro-Asian Economic Union, the situation is reversed there, but the tasks of developing EEU guidlines are completely different at this moment. So, we don't have any actors at this time who could manage any new guideline development.

And this article and similar we can be seen as "guideline" for understanding - as expert-officials think.

Complete thread:

Activity
 Admin contact
20,255 posts in 4,263 threads, 1,398 registered users;
online 13 (0 registered, 13 guests [including 8 identified bots]).
Forum time (Europe/Vienna): 11:45 CET

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5